Login to Your Account

QureInvest Raises $24.5M for Start-ups, Closes First Deal

By Cormac Sheridan

Wednesday, January 14, 2009
The team behind two recent successful start-ups, U3 Pharma AG and NeurImmune Therapeutics AG, is applying the lessons learned from those ventures to a new investment fund and has already completed its first deal, a CHF10 million (US$8.9 million) Series A round in start-up firm CT Atlantic AG. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription